A

AbbVie

Global biopharmaceutical company developing medicines

Senior IAM Directory Services Engineer M&A

Full-TimeUpdated on 10/23/2026
$96.5k - $183.5k/yr+ Short-term incentive
Senior
Bachelor's, Master's, PhD
North Chicago, IL, USA
Hybrid
CybersecuritySecurity Engineering & Architecture

About the job

Requirements
  • A Bachelor's degree with six years of experience, a Master's degree with five years of experience, or a PhD with zero years of experience.
  • Demonstrated experience in an information security role, ideally as a Security Engineer or Engineer.
  • Direct experience with M&A, divestitures, or multi-company collaborations.
  • Familiarity with self-hosted and cloud security tools and platforms.
  • Experience with cloud identity providers such as Entra, Okta, or PingOne supporting SAML, OIDC, and OAuth 2.0.
  • Working knowledge of AWS, GCP, or Azure, and collaboration tools such as M365, GSuite, or Slack, including integrations with cloud identity providers.
  • Proficiency in Active Directory and related security constructs, including domains, forests, and trusts.
  • Knowledge of identity and access governance policies and standards, including least privilege, access lifecycle management, and enterprise security policy frameworks.
  • Ability to lead integration strategies and influence peers to achieve desired outcomes.
  • Communication and collaboration abilities.
Responsibilities
  • Partner with business development groups throughout company relationships, including research-sharing arrangements, acquisitions, and site divestitures.
  • Support initial cross-company communication integration, migrate users to AbbVie-managed devices, assist with application transitions, and decommission legacy environments.
  • Serve as the primary liaison between the Identity team and technical and business stakeholders to develop, coordinate, and implement secure identity designs at strategic and operational levels.
  • Provide advisory services to reduce risk and technical friction in transactions.
  • Lead technical onboarding and identity integration for newly acquired entities, ensuring access to AbbVie systems and resources.
  • Design and implement identity federation and trust models across multiple domains and forests.
  • Drive migration of users, devices, and applications from legacy environments to standardized platforms.
  • Develop and maintain automation scripts and workflows for identity provisioning and deprovisioning during M&A transitions.
  • Maintain documentation and continuously improve M&A identity playbooks and standards.
  • Serve as a subject matter expert in identity architecture during due diligence and post-merger integration.
Desired Qualifications
  • Five years of experience in an information security role, ideally as an Identity or Security Engineer.
  • Practical experience in security architecture, such as Cloud Security, AppSec, Network Security, or Identity, and ability to discuss designed and implemented solutions.
  • Identity-focused certifications, such as Microsoft Certified: Identity and Access Administrator, Okta Certified Professional or Consultant, or Ping Identity certifications.
  • Familiarity with industry standards such as NIST 800 and ISO 27001.
  • Relevant certifications, such as SANS or AWS.

About the company

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Oct 22nd, 2026
Abbott stock: $247,767 in shares yields $500 a month in dividends ahead of Q3 earnings

Abbott Laboratories will report third-quarter earnings before the market opens on Wednesday, October 21. Analysts expect earnings of $1.41 per share, up from $1.30 a year earlier, and revenue of $12.99 billion, against $11.37 billion last year. On October 16, TD Cowen analyst Joshua Jennings reiterated a Buy rating and a $135 price target. Abbott pays a quarterly dividend of 63 cents per share ($2.52 a year), a yield of 2.42%. To earn $500 a month ($6,000 a year) from dividends alone, an investor would need about 2,381 shares, or roughly $247,767.

Yahoo Finance
Oct 21st, 2026
Retirees swap Social Security for 5 dividend stocks yielding up to 6.64%

Retirees looking for income beyond Social Security are turning to dividend stocks. The 2027 cost-of-living adjustment is tracking toward 3.3%, and five companies from different industries were screened for dividend safety first, then yield. Verizon yields 6.64% and Altria 6.17%. Verizon's free cash flow guidance of $21.94 billion to $22.14 billion covers its roughly $11.76 billion annual dividend. Altria's payout is about 79% of the low end of its 2026 earnings guidance. Realty Income pays monthly at a 5.99% yield and has raised its dividend 115 consecutive quarters. Enbridge yields 5.95%. AbbVie yields 2.48%, but its quarterly dividend has grown from $0.40 in 2013 to $1.73 in 2026. Risks include satellite competition for Verizon, falling cigarette volumes for Altria, and currency swings for Enbridge.

Yahoo Finance
Oct 19th, 2026
Merck and AbbVie shares jump 39% and 24% in 2026 as dividend picks for a decade

Healthcare stocks are rebounding in 2026, led by Merck and AbbVie. Merck shares have climbed 39% and AbbVie's 24%, against about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating Wall Street estimates. Keytruda sales hit $8.4 billion, though the drug will likely lose patent exclusivity by 2028. A subcutaneous version, Keytruda Qlex, may help retain market share. Merck's forward dividend yield is 2.3%. AbbVie's revenue grew 10.2% to almost $17 billion, with adjusted earnings per share up 22.9% to $3.65. Skyrizi and Rinvoq sales each rose about 24%, and neither faces US competition until 2033 and 2037 respectively. AbbVie has raised its dividend for 54 straight years, including its time as part of Abbott Laboratories.

Yahoo Finance
Oct 19th, 2026
Buffett warns of a "gambling mood" in markets; Vertex, Eli Lilly and AbbVie built to weather a drop

Warren Buffett, now Berkshire Hathaway's chairman emeritus, gave his bluntest warning yet at the May shareholder meeting. "We've never had people in a more gambling mood than now," he told CNBC, pointing to individuals rushing into short-term options and betting on markets. He said this behaviour is risky for those taking part and may threaten the market, possibly leading to a drop. The article suggests drugmakers as defensive picks, since patients need treatments in any economy. Vertex Pharmaceuticals leads in cystic fibrosis treatment. Eli Lilly's tirzepatide drugs, Mounjaro and Zepbound, earned more than $14 billion of its $23 billion quarterly revenue. AbbVie's Rinvoq and Skyrizi each grew 24%, and it has raised its dividend for more than 50 consecutive years.

Yahoo Finance
Oct 18th, 2026
Ken Griffin's Citadel boosts AbbVie stake 546% in Q2 as defensive dividend play

Citadel founder and chief executive officer Ken Griffin made healthcare his biggest bet in the second quarter. He bought 2.7 million AbbVie shares, a 546% increase from the previous quarter, and added 6.7 million shares of Abbott Laboratories, up 349%. He also raised his Eli Lilly stake by 291%, the third-biggest individual equity add. The moves suggest a defensive stance. Healthcare stocks tend to hold up in downturns, and both AbbVie and Abbott are Dividend Kings, having raised dividends for 54 straight years. AbbVie yields 2.65% and trades at 16 times forward earnings. In the second quarter, its adjusted earnings rose 23% and net revenue rose 10%. Some 75% of analysts covering the stock rate it a buy.